Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.India has rejected a drug patent application for Abbott's drug combination, Lopinavir/Ritonavir, which is indicated for the treatment of HIV positive patients who have failed to stay healthy with the first round of medicines currently available.
Subscribe to our email newsletter
The rejection of this patent application by The Indian Patent Office was for a combination of existing drugs and techniques.
Following this decision, India can now supply this drug to patients across the world, who are waiting for HIV treatment.
Initiative for Medicines, Access & Knowledge (I-MAK), the not-for-profit organisation, has initiated the legal action over this patent application.
I-MAK Director, Tahir Amin said that Abbott’s track record on pricing this drug unfairly for poorer countries motivated the organisation to take on the case.